Étiquette : ptsd

Cannabinoid Regulation of Fear and Anxiety : an Update, Eleni P. Papagianni & Carl W. Stevenson, 2019

Cannabinoid Regulation of Fear and Anxiety : an Update Eleni P. Papagianni & Carl W. Stevenson Current Psychiatry Reports, 2019, 21, 38 doi : 10.1007/s11920-019-1026-z   Abstract Purpose of Review : Anxiety- and trauma-related disorders are prevalent and debilitating mental illnesses associated with a significant socioeconomic burden. Current treatment approaches often have inadequate therapeutic responses, leading to symptom relapse. Here we review recent preclinical and clinical findings on the potential of cannabinoids as novel therapeutics for regulating fear and anxiety. Recent Findings : Evidence from preclinical studies has shown that the non-psychotropic phyto-cannabinoid cannabidiol and the endocannabinoid anandamide have acute anxiolytic effects and also regulate learned fear [...]

Lire la suite

Medical cannabis trial will target 20,000 UK patients, Jamie Doward and Lily Gordon Brown, The Guardian, 3 novembre 2019.

Medical cannabis trial will target 20,000 UK patients Jamie Doward and Lily Gordon Brown The GUARDIAN, Published on Sun 3 Nov 2019 https://www.theguardian.com/society/2019/nov/03/medical-cannabis-uk-clinical-trial-patients-nhs   Project backed by Royal College of Psychiatrists aims to be largest on drug’s use in Europe • Medical cannabis: Why are doctors still not prescribing it? Tilray medicinal cannabis growing facility in Canada. Photograph: Tilray Up to 20,000 patients in the UK are to be given medical cannabis over a two-year period in an initiative that aims to create the largest body of evidence on the drug in Europe. The move, to be unveiled on Thursday, is [...]

Lire la suite

Medical cannabis and mental health : A guided systematic review, Zach Walsh et al., 2017

Medical cannabis and mental health : A guided systematic review, Zach Walsh, Raul Gonzalez, Kim Crosby, Michelle S. Thiessen, Chris Carroll, Marcel O. Bonn-Miller Clinical Psychology Review, 2017, 51, 15-29. Doi : 10.1016/j.cpr.2016.10.002   a b s t r a c t This review considers the potential influences of the use of cannabis for therapeutic purposes (CTP) on areas of interest to mental health professionals, with foci on adult psychopathology and assessment. We identified 31 articles relating to the use of CTP and mental health, and 29 review articles on cannabis use and mental health that did not focus on use for therapeutic purposes. Results reflect the [...]

Lire la suite

Psychedelics : Where we are now, why we got here, what we must do, Sean J. Belouin & Jack E. Henningfield, 2018

Psychedelics : Where we are now, why we got here, what we must do Sean J. Belouin, Jack E. Henningfield Neuropharmacology, 2018, 142, 7e19 https://doi.org/10.1016/j.neuropharm.2018.02.018 a b s t r a c t The purpose of this commentary is to provide an introduction to this special issue of Neuropharmacology with a historical perspective of psychedelic drug research, their use in psychiatric disorders, research restricting regulatory controls, and their recent emergence as potential breakthrough therapies for several brain-related disorders. It begins with the discovery of lysergic acid diethylamide (LSD) and its promising development as a treatment for several types of mental illnesses during the 1940s. This was [...]

Lire la suite

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis, Nicola Black et al., 2019,

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis Nicola Black, Emily Stockings, Gabrielle Campbell, Lucy T. Tran, Dino Zagic, Wayne D. Hall, Michael Farrell, Louisa Degenhardt Lancet Psychiatry, 2019 https://doi.org/10.1016/S2215-0366(19)30401-8   Summary Background : Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental disorders. Methods : For this systematic review and meta-analysis [...]

Lire la suite

Using Cannabis To Help You Sleep: Heightened Frequency of Medical Cannabis Use among Those with PTSD, Marcel O. Bonn-Miller et al., 2014,

Using Cannabis To Help You Sleep: Heightened Frequency of Medical Cannabis Use among Those with PTSD Marcel O. Bonn-Miller, Kimberly A. Babson, and Ryan Vandrey Drug and Alcohol Dependence, 2014, 136, 162–165. doi:10.1016/j.drugalcdep.2013.12.008   Abstract Background : The use of cannabis for medical purposes is proliferating in the U.S., and PTSD is an explicitly approved condition for accessing medical cannabis in 5 states. Prior research suggests that people with PTSD often use cannabis to help cope with their condition, and that doing so results in more frequent and problematic cannabis use patterns. Specific coping motivations, such as sleep improvement, among medical cannabis users, have not been [...]

Lire la suite

Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users, 2014

Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users M.O. Bonn-Miller, M.T. Boden, M.M. Bucossi, K.A. Babson The American Journal of Drug and Alcohol Abuse, 2014, 40, (1), 23-30. doi : 10.3109/00952990.2013.821477.   OBJECTIVES Little research has investigated the demographic and symptom profile of medical cannabis users in states in the USA that have legalized cannabis use. METHODS In the present cross-sectional study, we investigated the demographic profile of 217 adults currently receiving medical cannabis, as well as differences in problematic use and perceived helpfulness in terms of (i) symptoms of psychological disorders and pain, and (ii) motives for use. RESULTS Findings indicated that medical cannabis users (i) [...]

Lire la suite

Why Psychiatry Needs 3,4 Methylenedioxymethamphetamine : A Child Psychiatrist’s Perspective, Ben SESSA, 2017

Why Psychiatry Needs 3,4 Methylenedioxymeth-amphetamine : A Child Psychiatrist’s Perspective Ben SESSA Neurotherapeutics, 2017, 14, (3), 741-749. doi:10.1007/s13311-017-0531-1 Abstract Since the late 1980s the psychoactive drug 3,4-methylenedioxymethamphetamine (MDMA) has had a well-known history as the recreationally used drug ecstasy. What is less well known by the public is that MDMA started its life as a therapeutic agent and that in recent years an increasing amount of clinical research has been undertaken to revisit the drug’s medical potential. MDMA has unique pharmacological properties that translate well to its proposed agent to assist trauma-focused psychotherapy. Psychological trauma—especially that which arises early in life from child abuse—underpins many [...]

Lire la suite

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity, Robin L. Carhart-Harris et al., 2015

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity Robin L. Carhart-Harris, Kevin Murphy, Robert Leech, David Erritzoe, Matthew B. Wall, Bart Ferguson, Luke T.J. Williams, Leor Roseman, Stefan Brugger, Ineke De Meer, Mark Tanner, Robin Tyacke, Kim Wolff, Ajun Sethi, Michael A.P. Bloomfield, Tim M. Williams, Mark Bolstridge, Lorna Stewart, Celia Morgan, Rexford D. Newbould, Amanda Feilding, H. Val Curran, and David J. Nutt Biological Psychiatry, 2015, 78, 554-562. http://dx.doi.org/10.1016/j.biopsych.2013.12.015   ABSTRACT BACKGROUND : The compound 3,4-methylenedioxymethamphetamine (MDMA) is a potent monoamine releaser that produces an acute euphoria in most individuals. METHODS : [...]

Lire la suite